Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dryvax Dose-Response Study
NCT00026611Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- Dec 2001
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dryvax in smallpox (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of subjects with successful vaccine take (vesicle or pustule formation). Status: completed.
02
Drugs
dryvax
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00026611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026611.